I originally posted this elsewhere, but I thought I’d keep track of it — for ease of future reference — here:
“. . . .Abbott [today] announced new data from the open-label extension of the ATLAS (Adalimumab Trial Evaluating Long-Term Efficacy and Safety in AS) phase III clinical trial, which showed HUMIRA® (adalimumab) reduced the signs and symptoms of ankylosing spondylitis (AS) for up to three years of treatment among 74 percent of patients tested. AS is a type of arthritis that primarily causes inflammation of the spine and the spinal joints. . . .”
So, Abbott’s tried and true mature drug, Humira, looks to be both safe and effective against ankylosing spondylitis (AS), for at least three year horizons — which makes SGP’s candiate, not yet cleared in Europe, for the AS indication, considerably less valuable.
Or so it would seem, to this experienced observer.